Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption - Wikidata - awgldk - TriplyDB

Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption

Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption

http://www.wikidata.org/entity/Q34997337

about

VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex Modes of resistance to anti-angiogenic therapy Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis Pharmacologic resistance in colorectal cancer: a review Sequence of treatment in locally advanced and metastatic renal cell carcinoma Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme Advanced magnetic resonance imaging methods for planning and monitoring radiation therapy in patients with high-grade glioma Intertwined regulation of angiogenesis and immunity by myeloid cells Twisted tango: brain tumor neurovascular interactions Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma Imaging of Angiotropism/Vascular Co-Option in a Murine Model of Brain Melanoma: Implications for Melanoma Progression along Extravascular Pathways.Regenerative therapeutic potential of adipose stromal cells in early stage diabetic retinopathy Escaping Antiangiogenic Therapy: Strategies Employed by Cancer Cells Adaptation to antiangiogenic therapy in neurological tumors A PK2/Bv8/PROK2 antagonist suppresses tumorigenic processes by inhibiting angiogenesis in glioma and blocking myeloid cell infiltration in pancreatic cancer MiR-15b and miR-152 reduce glioma cell invasion and angiogenesis via NRP-2 and MMP-3 Computer simulation of glioma growth and morphology.Inositol-requiring enzyme 1alpha is a key regulator of angiogenesis and invasion in malignant glioma Glioma-related edema: new insight into molecular mechanisms and their clinical implications.Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy.Imaging biomarkers for antiangiogenic therapy in malignant gliomas.Post-treatment imaging changes in primary brain tumors.Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer.Therapeutic strategies for inhibiting invasion in glioblastoma.Isolation of targeting nanobodies against co-opted tumor vasculature.Advanced imaging techniques in brain tumors.Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme.Histidine-rich glycoprotein can prevent development of mouse experimental glioblastoma.Novel target for peptide-based imaging and treatment of brain tumors VEGF inhibition and metastasis: possible implications for antiangiogenic therapy.A new mosaic pattern in glioma vascularization: exogenous endothelial progenitor cells integrating into the vessels containing tumor-derived endothelial cells.Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes Multiparameter computational modeling of tumor invasion.Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma Revisiting the hallmarks of cancer.Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.

P2860

Q24293027-E6A8083A-BF36-4C28-9D2E-A689841B1D86 Q24608005-F5F770D4-7D1A-4F2A-82BC-BB9B5CB4602D Q24608039-CC6B6B2F-6CE3-4999-8EF9-F9B0A83CBF6E Q26769850-DBC57E21-8101-4D9C-9BCA-5CD2BC8489B5 Q26773653-53EF4611-9CEE-417E-81D1-D902B47D522A Q26824557-D3A814FE-A96E-46A4-895B-B532DC2EFE33 Q26826862-31DCBAC3-5972-4807-9A1A-D7C8B82C052E Q26830418-1D089B5C-F605-4CAE-ABC3-B5EA4C1D0BF3 Q26849613-863C9BC5-623A-4E57-BE3C-1679D231C4EE Q27016629-957E6AA2-CAE5-4EFD-A073-E0A000B5B09A Q27021470-38346EDF-E43B-49DF-94BD-9C4B364B38D7 Q27324507-3FE2398A-C7F5-4912-B1DB-523F42E46CA9 Q27334841-3510B04E-E3F5-4C03-9DFD-A0BBD21D0503 Q28067753-A0363B85-E991-40A8-B326-FE2C056BB558 Q28082908-D3864C4D-E241-44F1-A9CD-85B6568D920B Q28485246-4748B206-1A7A-4C25-9F44-6E910FDFE66F Q28564217-ECAEDEFC-B2E6-41B8-8E80-96A076AFB027 Q30481298-03C46998-623F-4EBF-8EC1-7439B12305AD Q30496396-12C0A794-C802-4DB6-89BF-F24687A1AEBE Q30581454-EABA39C0-5018-45A5-B435-54154644194A Q30607148-ACCB0517-3337-4A74-9C2D-F0583F49B25D Q30764736-CE9C3172-0D03-449D-B428-A6C4D24829B1 Q30835236-5A4E525B-CED4-40A2-A420-B4426C9F149D Q33382708-8252E5BE-FBC6-40D7-B09D-47BA881FC931 Q33388438-BF3474D3-1DDC-4611-A38B-C5EF719FC4CB Q33397569-CD94DE67-BE11-4000-BFDC-BEDD5E9F2180 Q33424301-39152EA5-27C1-45EE-BA9B-4F0C79865588 Q33426563-E1B5F95C-B2A7-4CA3-94B7-6C06A50181D2 Q33509984-D46F042A-5EE1-4980-8A2C-971B9271D32E Q33517391-4CEB33DA-A29E-4B71-86E2-79E54D783E6D Q33518926-2CDFAB84-9B55-4454-88C8-BBCFF14FBC13 Q33521707-7DD5F277-6ED9-4A14-8933-515F64E635E0 Q33554409-AA68EE80-026B-4D77-B2D7-A2A938268F39 Q33573974-EC82C424-C4AC-4424-8EE6-626D2EB6D06D Q33688374-451E59BE-B419-4FCD-831E-AB1A60DA7950 Q33688579-254D4133-FBB8-4D03-B009-54DA449FAE72 Q33716257-B893B564-9954-49BA-A88C-F324FE023AF6 Q33731698-E5540410-AB02-465F-AC2F-610FABBF715C Q33732986-F2DAB0FB-2196-412E-BCA3-DA50333BB899 Q33770680-B16070C1-5D7A-4630-BED0-BC01E766FA55

P2860

Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption

http://www.wikidata.org/entity/Q34997337

description

2000 nî lūn-bûn

@nan

2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Anti-VEGF antibody treatment o ...... in increased vascular cooption

@ast

Anti-VEGF antibody treatment o ...... in increased vascular cooption

@en

Anti-VEGF antibody treatment o ...... in increased vascular cooption

@nl

type

label

Anti-VEGF antibody treatment o ...... in increased vascular cooption

@ast

Anti-VEGF antibody treatment o ...... in increased vascular cooption

@en

Anti-VEGF antibody treatment o ...... in increased vascular cooption

@nl

prefLabel

Anti-VEGF antibody treatment o ...... in increased vascular cooption

@ast

Anti-VEGF antibody treatment o ...... in increased vascular cooption

@en

Anti-VEGF antibody treatment o ...... in increased vascular cooption

@nl

P1433

Q34997337-7DB24B1B-4D15-412D-A449-17DAAF786C80

P1476

Q34997337-BFE4967C-30BF-4C8F-9CB1-5988DC55495A

P2093

Q34997337-03951A9F-D7EC-4BB8-B082-A140D573D24C

Q34997337-1884FE00-0470-4964-B5A4-35872A8057F5

Q34997337-37EB6178-176C-404F-9AD2-861116FC9E67

Q34997337-6C43A151-31B3-487F-96D4-F96370CC193E

Q34997337-B029CDB8-CB5D-456D-93BF-80791B30B42C

Q34997337-C2335C14-8EC4-4601-BFEA-F3FEE145BCFB

Q34997337-F0416DCA-EA5D-4034-AF38-D9EB234A1280

P2860

Q34997337-099C7419-D713-4E7C-81FF-44C25706981E

Q34997337-0BE7BFAA-D6C6-4857-B06B-50B552A6529B

Q34997337-1124E850-1C29-40D7-9A4A-057E4905AEE7

Q34997337-22C3CA40-C859-4E66-942D-4ECB5C0DF661

Q34997337-56BA4A31-52B3-42A2-9C42-335ABAAD8EAF

Q34997337-58CFC189-5C5A-4954-B439-B172683146AA

Q34997337-5CB5F3B9-5847-4E23-8C00-9125EEA9F1F2

Q34997337-5DCC1301-B45B-4C71-B6DC-4C24384AA893

Q34997337-8C5DE070-D371-4902-9A6C-80786C61188E

Q34997337-9E5E334A-B9EE-4008-880F-456EB4795EDA

P304

Q34997337-C6CCC82B-E017-4742-A347-7F0EFFCDF905

P31

Q34997337-8FC1EA6B-A7DE-4CF3-BE29-07DD1068F797

P356

Q34997337-021C2710-3B3F-43C3-9463-A3A2A7A2842D

P433

Q34997337-2BFCE3CA-4E19-4F4E-B2FD-206219ED553A

P478

Q34997337-B20C9B60-49B6-4642-8008-AC67A9DCD80F

P577

Q34997337-B1F46C40-90A9-4D15-B603-BB0324ADB542

P5875

Q34997337-3B36EF4F-BEAF-40B3-96A7-C480D0A80167

P698

Q34997337-9E008403-EB33-4A51-962B-640D7658C5B1

P921

Q34997337-56CB5273-E0AD-4771-A8E3-4417861563F4

P932

Q34997337-4410C0B5-BB6C-4C3C-A423-9172609EDE55

P356

P1433

P1476

Anti-VEGF antibody treatment o ...... in increased vascular cooption

@en

P2093

D F Deen

http://www.w3.org/2001/XMLSchema#string

J Kim

http://www.w3.org/2001/XMLSchema#string

J L Rubenstein

http://www.w3.org/2001/XMLSchema#string

M A Shuman

http://www.w3.org/2001/XMLSchema#string

M Westphal

http://www.w3.org/2001/XMLSchema#string

M Zhang

http://www.w3.org/2001/XMLSchema#string

T Ozawa

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model.

Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms.

Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor.

Antiangiogenic therapy of transgenic mice impairs de novo tumor growth

Karyotype analyses of 20 human glioma cell lines.

Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.

Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo.

P304

306-314

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.NEO.7900102

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2000-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12317162

http://www.w3.org/2001/XMLSchema#string

P698

11005565

http://www.w3.org/2001/XMLSchema#string

P921

P932

1550290

http://www.w3.org/2001/XMLSchema#string